Showing results (451-460 of 844) with videos related to

Sort By:
Pageof 85
Cancer Treatment Reviews|November 5, 2013
Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunitiesAngela Esposito, Alberto Bardelli, Carmen Criscitiello, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 25, 2015
Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancerG Pruneri, A Vingiani, V Bagnardi, et al.
Annals of Internal Medicine|June 15, 1992
Quality-of-life evaluation in a clinical trial of zidovudine therapy in patients with mildly symptomatic HIV infection. The AIDS Clinical Trials GroupR D Gelber, W R Lenderking, D J Cotton, et al.
BMC Cancer|September 19, 2006
Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancerLaura Orlando, Anna Cardillo, Raffaella Ghisini, et al.
European Journal of Cancer (Oxford, England : 1990)|May 18, 2010
A nomogram based on the expression of Ki-67, steroid hormone receptors status and number of chemotherapy courses to predict pathological complete remission after preoperative chemotherapy for breast cancerMarco Colleoni, Vincenzo Bagnardi, Nicole Rotmensz, et al.
International Journal of Clinical Oncology|April 12, 2014
Estramustine phosphate sodium in heavily pretreated patients with metastatic breast cancer: a retrospective consecutive case seriesGaetano Aurilio, Rossella Graffeo, Vincenzo Bagnardi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 23, 2012
Dimerization of NKp46 receptor is essential for NKp46-mediated lysis: characterization of the dimerization site by epitope mappingMichal Jaron-Mendelson, Rami Yossef, Michael Y Appel, et al.
Breast Cancer Research and Treatment|April 28, 2004
Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trialBeat Thürlimann, Dagmar Hess, Dieter Köberle, et al.
Cancer Treatment Reviews|December 16, 2014
Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatmentCarmen Criscitiello, Giulia Viale, Lucia Gelao, et al.
Breast (Edinburgh, Scotland)|February 27, 2009
Bone Quality Test (BQT) scores of fingernails in postmenopausal patients treated with adjuvant letrozole or tamoxifen for early breast cancerZhuoxin Sun, Aron Goldhirsch, Karen N Price, et al.
Pageof 85